FORT WASHINGTON, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, May 10, 2016 at 4:30 p.m. EDT to discuss first quarter 2016 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 1781961 five to 10 minutes before the start of the call.
A live audio webcast of the call will also be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. Please log on through Vitae's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORgt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com.
INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 email@example.com Westwicke Partners John Woolford (443) 213-0506 firstname.lastname@example.org MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 email@example.com
Source:Vitae Pharmaceuticals, Inc.